Long term treatment with Eptinezumab: real world data

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035667

Enrollment

Registered

2024-12-16

Start date

2024-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G43.1 G43.0 G43.1 G43.0

Interventions

Group 1: The study included patients with episodic or chronic migraine who started treatment with eptinezumab between 2018 and March 2024. Headache-specific data (headache days, analgesic days and hea

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Migraine diagnosis Therapy with eptinezumab Headache diary

Exclusion criteria

Exclusion criteria: missing headache diary

Design outcomes

Primary

Measure	Time frame
reduction of monthly migraine days	—

Secondary

Measure	Time frame
change in the monthly analgetic days and monthly headache intensity	—

Countries

Germany

Contacts

Public ContactGudrun Goßrau

Universitäts Schmerzcentrum Universitätsklinikum Dresden

gudrun.gossrau@ukdd.de03514583354

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026